Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite by Skledar, Darja Gramec et al.
1 
 
Endocrine Activities and Adipogenic Effects of Bisphenol AF and Its Main Metabolite   1 
 2 
 3 
Darja Gramec Skledara, Adriana Carinob, Jurij Trontelja, Johanna Trobergc, Eleonora 4 
Distruttib, Silvia Marchianòb, Tihomir Tomašiča, Anamarija Zegaa, Moshe Finelc, Stefano 5 
Fioruccib, Lucija Peterlin Mašiča* 6 
 7 
 8 
aFaculty of Pharmacy, University of Ljubljana, Aškerčeva 7, 1000 Ljubljana, Slovenia 9 
bDipartimento di Medicina Clinica e Sperimentale, Nuova Facultà di Medicina e Chirurgia, 10 
University of Perugia, S. Andrea delle Fratte, 06132 Perugia, Italy 11 
cDivision of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, 12 




*Corresponding author: Lucija Peterlin Mašič 17 
Faculty of Pharmacy 18 
University of Ljubljana 19 
Aškerčeva 7 20 
1000 Ljubljana, Slovenia 21 
Tel: +386-1-4769635 22 
E-mail: lucija.peterlin@ffa.uni-lj.si 23 




Bisphenol AF (BPAF) is a fluorinated analog of bisphenol A (BPA), and it is a more potent 26 
estrogen receptor (ER) agonist. BPAF is mainly metabolized to BPAF-glucuronide (BPAF-27 
G), which has been reported to lack ER agonist activity and is believed to be biologically 28 
inactive. The main goal of the current study was to examine the influence of the 29 
metabolism of BPAF via glucuronidation on its ER activity and adipogenesis. Also, as 30 
metabolites can have different biological activities, the effects of BPAF-G on other nuclear 31 
receptors were evaluated. First, in-vitro BPAF glucuronidation was investigated using 32 
recombinant human enzymes. Specific reporter-gene assays were used to determine 33 
BPAF and BPAF-G effects on estrogen, androgen, glucocorticoid, and thyroid receptor 34 
pathways, and on PXR, FXR, and PPARγ pathways. Their effects on lipid accumulation and 35 
differentiation were determined in murine 3T3L1 preadipocytes using Nile Red, with 36 
mRNA expression analysis of the adipogenic markers adiponectin, Fabp4, Cebp, and 37 
PPAR. BPAF showed strong agonistic activity for hERα and moderate antagonistic 38 
activities for androgen and thyroid receptors, and for PXR. BPAF-G was antagonistic for 39 
PXR and PPARγ. BPAF (0.1 µM) and BPAF-G (1.0 µM) induced lipid accumulation and 40 
increased expression of key adipogenic markers in murine preadipocytes. BPAF-G is 41 
therefore not an inactive metabolite of BPAF. Further toxicological and epidemiological 42 
investigations of BPAF effects on human health are warranted, to provide better 43 
understanding of the metabolic end-elimination of BPAF. 44 
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BPA, bisphenol A; BPAF, bisphenol AF; BPAF-G, bisphenol AF glucuronide; BPS, bisphenol 51 
S; CDCA, chenodeoxycholic acid; DIM, differentiation mix (DMEM, 10% fetal calf serum, 52 
517 μM 3-isobutyl-1-methylxanthine, 1 μM dexamethasone, 172 nM insulin); DMEM, 53 
Dulbecco’s modified Eagle’s medium; E2, 17--estradiol; ER, estrogen receptor; FXR, 54 
farnesoid receptor; HIM, human intestine microsomes; HLM, human liver microsomes; 55 
NADPH, β-nicotinamide adenine dinucleotide phosphate; PBS, phosphate-buffered saline; 56 
PPAR, peroxisome proliferator-activated receptor; PXR, pregnane X receptor; T3, 57 
triiodothyronine; UDPGA, uridine 5’diphosphoglucuronic acid; UGT, 5'-diphospho-58 
glucuronosyltransferase 59 
  60 
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1. Introduction 61 
 62 
Bisphenol AF (BPAF; 1,1,1,3,3,3-hexafluoro-2,2-bis (4-hydroxyphenyl)propane) is a 63 
fluorinated analog of the endocrine-disrupting bisphenol A (BPA; Fig. 1). BPAF is 64 
extensively used in the production of fluoroelastomers and fluoropolymers, and it has 65 
already been detected in various environmental matrices near manufacturing plants, 66 
including rivers, soil, and sediment (Song et al., 2012). BPAF has also been detected in 67 
sewage sludge (up to 72.2 ng/g dry weight) (Yu et al., 2015), indoor dust (Liao et al., 68 
2012), and honey samples (up to 53.5 ng/mL) (Cesen et al., 2016). On the other hand, 69 
BPAF was not detected in canned and noncanned beverages (Regueiro and Wenzl, 2015a), 70 
nor in ready-made meals (Regueiro and Wenzl, 2015b). Currently, the estimated dietary 71 
intake of BPAF is 0.49 ng/kg body weight/day for men and 0.50 ng/kg body weight/day 72 
for women (Liao and Kannan, 2013). However, due to the extensive replacement of BPA 73 
by its analogs, it is likely that the exposure to BPAF and to the other BPA substitutes will 74 
rise in the coming years. 75 
In previous in-vitro studies, BPAF showed higher estrogen receptor (ER) agonistic 76 
activity than BPA (Table 1). This higher activity was defined using luciferase reporter 77 
assays in several cell lines, including MCF7 (Kitamura et al., 2005), MVLN (Song et al., 78 
2014), and CV-1 monkey kidney (Teng et al., 2013) cells. Similarly, ER agonistic activities 79 
for BPAF were shown in yeast cells (Fic et al., 2014; Ruan et al., 2015; Lei et al., 2016), and 80 
in in-vivo vitellogenin assays (Song et al., 2014).  81 
Bisphenol AF is mainly metabolized to its corresponding glucuronide (BPAF-G; Fig. 82 
1) and sulfate conjugates, both in vivo (Li et al., 2013; Feng et al., 2016) and in vitro 83 
(Waidyanatha et al., 2015). Formation of BPAF-G from BPAF in vivo is rapid and efficient. 84 
Indeed, for rats treated with 20 mg/kg BPAF, the BPAF-G peak was detected in plasma 30 85 
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min after oral administration (Li et al., 2013). Following oral administration in rats, BPAF-86 
G is mainly excreted in bile and is further deconjugated in the intestine to the parent BPAF 87 
(Waidyanatha et al., 2015). Li et al. (2013) also tested some uridine 5'-diphospho-88 
glucuronosyltransferases (UGTs), and reported that the main UGT involved in BPAF 89 
glucuronidation is UGT2B7, followed by UGT1A3, UGT2B15, UGT1A9, UGT2B17, UGT1A1, 90 
UGT1A8, and UGT2A4 (Li et al., 2013). As expected, the bisphenol glucuronides evaluated 91 
lacked ER agonistic activity; namely, BPA-glucuronide (BPA-G) (Matthews et al., 2001), 92 
bisphenol S (BPS)-glucuronide (BPS-G) (Skledar et al., 2016), and BPAF-G (Li et al., 2013). 93 
BPA-G has been considered to be an inactive BPA metabolite, although it cannot be 94 
regarded as completely inactive as it can induce adipocyte differentiation (Boucher et al., 95 
2015). BPA and BPS have metabolic effects and act as environmental obesogens, as they 96 
can induce lipid accumulation and increase expression of adipogenic markers in murine 97 
preadipocytes through peroxisome proliferator-activated receptor (PPAR)γ activation 98 
(Ahmed and Atlas, 2016). However, no such studies have been performed for BPAF, or its 99 
main metabolite. 100 
In addition to its estrogenic activity, BPAF has in-vitro androgen receptor 101 
antagonistic activity at low micromolar concentrations (Table 1), as demonstrated in 102 
yeast (Fic et al., 2014), and in NIH3T3 (Kitamura et al., 2005), CV1 (Teng et al., 2013) and 103 
MDA-kb2 (Kolšek et al., 2015) cells. BPAF is a relatively weak pregnane X receptor (PXR) 104 
activator compared to BPA (Sui et al., 2012). The thyroid hormone activities of bisphenols 105 
were evaluated by measuring growth-hormone production in GH3 cells, an assay in which 106 
BPAF was inactive (Kitamura et al., 2005). In contrast, using yeast two-hybrid assays, 107 
BPAF was shown to have thyroid hormone receptor agonistic activity that was greater 108 
than that of BPA (Table 1) (Lei et al., 2016). Additionally, disruption of thyroid hormone 109 
activity was shown in zebrafish larvae, which resulted in a robust decrease in thyroid 110 
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hormone levels and disruption of gene transcription in the hypothalamic–pituitary–111 
thyroid axis (Tang et al., 2015).  112 
Bisphenol AF also has the highest DNA-damaging potential among several 113 
bisphenols in human peripheral blood mononuclear cells (Mokra et al., 2016). This was 114 
shown using alkaline and neutral versions of the comet assay, where BPA and BPAF 115 
induced single-strand breaks in DNA even at 10 ng/mL. BPAF had higher spermatogonial 116 
toxicity in comparison to BPA and BPS, which included dose-dependent and time-117 
dependent alterations in nuclear morphology, the cell cycle, and DNA damage responses, 118 
and perturbation of the cytoskeleton (Liang et al., 2017). In an in-vivo study on aquatic 119 
organisms, BPAF had greater toxicity toward Daphnia magna, Danio rerio, and 120 
Desmodesmus subspicatus compared to BPA and BPF (Tisler et al., 2016). 121 
We have previously used physiologically based pharmacokinetic models models to 122 
compare internal exposure to BPA, BPS, BPF, and BPAF after peroral and dermal exposure in 123 
different age groups (Karrer et al., 2018). BPAF glucuronidation in microsome preparations 124 
from human liver (HLMs) and intestine (HIMs) followed substrate inhibition kinetics, 125 
which reached maximum inhibition well below 100 μM. At higher substrate 126 
concentrations, the BPAF glucuronidation rate was slower than that of BPA, BPS, and BPF. 127 
However, under realistic exposure conditions, the BPAF glucuronidation rate would be 128 
expected to be greater than that of other BPA analogs (Karrer et al., 2018). As 129 
glucuronidation was reported as the main metabolic pathway for BPAF, in the present 130 
study we performed a detailed in-vitro analysis of BPAF glucuronidation using 17 131 
recombinant human UGTs, which included UGTs that are not commercially available, with 132 
the addition of HLMs and HIMs. As BPAF-G was not commercially available, we performed 133 
enzyme-assisted synthesis of BPAF-G using the human recombinant enzyme UGT2A1 (see 134 
Data in Brief). To date, BPAF-G has been tested only in terms of its estrogenic activity; 135 
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however, in the present study, we compared the activities of BPA, BPAF, and BPAF-G on 136 
ER, androgen receptor, glucocorticoid receptor, and thyroid receptor pathways, and on 137 
PXR, PPARγ, and farnesoid receptor (FXR) pathways, using in-vitro reporter gene assays. 138 
In addition, the effects of BPAF and BPAF-G on lipid accumulation and differentiation of 139 
the murine 3T3L1 preadipocyte cell line were examined. The results of the present study 140 
show that BPAF-G is not an inactive metabolite, as it has antagonistic activities toward 141 
nuclear receptor pathways, induces lipid accumulation in murine preadipocytes, and 142 
increases expression of several key adipogenic markers at the mRNA level. 143 
 144 
2. Materials and methods 145 
 146 
2.1. Materials 147 
Bisphenol AF (97%; CAS 1478-61-1), BPA (99%; CAS 80-05-7), β-nicotinamide adenine 148 
dinucleotide phosphate (NADPH, reduced tetra(cyclohexylammonium) salt; CAS 100929-149 
71-3), L-glutathione (≥98%; CAS 70-18-8), uridine 5’diphosphoglucuronic acid (UDPGA; 150 
ammonium salt; 98%-100%, CAS 43195-60-4), alamethicin (CAS 27061-78-5), sodium 151 
phosphate monobasic, anhydrous (>98%; CAS 7558-80-7), magnesium chloride (≥98%; 152 
CAS 7786-30-3), insulin (CAS I9278), isobutylmethylxanthine (CAS I5879), dimethyl 153 
sulfoxide and dexamethasone were all from Sigma-Aldrich (St. Louis, MO, USA). BPAF-G 154 
was biosynthesized in the Faculty of Pharmacy, University of Ljubljana (Slovenia), as 155 
described in the Data in Brief. Pooled human liver microsomes (HLMs; 20 mg/mL), pooled 156 
human intestinal microsomes (HIMs; 20 mg/mL) and recombinant human UGT2B15 157 
‘supersomes’ were from BD Biosciences (Franklin Lakes, NJ, USA). Recombinant human 158 
UGTs 1A1, 1A3-1A10, 2A1-2A3, 2B4, 2B7, 2B17, and 2B28 were produced in the Division 159 
of Pharmaceutical Chemistry, University of Helsinki (Finland). Methanol and acetonitrile 160 
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were liquid chromatography–mass spectrometry grade, and were from Sigma-Aldrich (St. 161 
Louis, MO, USA). 17--Estradiol (E2, ≥98%, CAS 50-28-2), dihydrotestosterone (≥98%, 162 
CAS 521-18-6), hydrocortisone (≥98%, CAS  50-23-7), flutamide (≥99%, CAS  13311-84-163 
7), mifepristone (≥98%, CAS 84371-65-3), 3,3´,5-triiodo-L-thyronine (T3, ≥95%, CAS 164 
6893-02-3), ethanolamine (≥99%, CAS 141-43-5), sodium selenite (≥98%, CAS 10102-18-165 
8), human apotransferin (≥98%, CAS 11096-37-0), bovine serum albumin (≥98%, CAS 166 
9048-46-8), 17--estradiol (≥98%, CAS 57-91-0), corticosterone (≥98.5%, CAS 50-22-6), 167 
tamoxifen (≥99%, CAS 10540-29-1) and kanamycin solution from Streptomyces 168 
kanamyceticus (10 mg/mL, CAS 25389-94-0) were from Sigma-Aldrich, Germany. HepG2 169 
cells were from American Type Culture Collection (ATCC HB-8065; LGC Standards S.r.l., 170 
Italy). 3T3-L1 cells were from the Health Protective Agency culture collection, and were 171 
supplied by Sigma Aldrich (St. Louis, MO, USA). FuGENE (R) HD Transfection Reagent 172 
(E2311) and the Dual-Luciferase(R) Reporter assay system (E1980) were from Promega 173 
Italia S.r.l. (Milan, Italy). TRIzol reagent (REF 15596026), DNaseI (REF 18068-015), and 174 
SuperScriptII (REF 18064-014) were from Invitrogen. SYBR Select Master Mix (REF 175 
4472908) was from Applied Biosystems. Alexafluor488-conjugated phalloidin and Nile 176 
Red solution were from ThermoFisher Scientific. 177 
 178 
2.2. Glucuronidation assay 179 
Bisphenol AF glucuronidation activity was tested with both recombinant human UGTs 180 
and pooled HLMs and HIMs. Stock solutions of BPAF were prepared in methanol. The 181 
reaction mixture (final volume, 100 µL) contained 50 mM phosphate buffer, pH 7.4, 10 182 
mM MgCl2, 20 µM or 50 µM BPAF, and the enzyme source (final concentration, 0.2 mg 183 
protein/mL). To avoid solubility problems, 2% dimethylsulfoxide was also added to the 184 
reaction mixture. In assays with microsomes, the reaction mixture also contained 185 
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alamethicin (final concentration, 5% of total microsomal protein concentration). These 186 
reaction mixtures were incubated on ice for 30 min, and then at 37 °C for 5 min. The 187 
reactions were started by addition of UDPGA (final concentration, 5 mM), and following a 188 
60-min incubation at 37 °C, 10 µL 70% perchloric acid was added, to terminate the 189 
reaction. The samples were then transferred to ice for 15 min, centrifuged at 16000× g for 190 
10 min, and the supernatants were subjected to HPLC analysis. The assays were 191 
performed in triplicate. Control samples (i.e., without UDPGA, without substrate) were 192 
included in each set of assays.  193 
The HPLC-UV analyses were performed using an Agilent 1100 series HPLC system 194 
(Agilent Technologies, Palo Alto, CA, USA) equipped with a Poroshell 120 EC-C18 column 195 
(4.6 × 100 mm, 2.7 µm; Agilent Technologies) that was maintained at 40 °C, with a flow 196 
rate of 1 mL/min. The BPAF and BPAF-G separation was achieved using the mobile phases 197 
of 0.1% formic acid (A) and acetonitrile (B), as follows: 03 min, 35% B; 36 min, 198 
35%65% B; 68 min, 65% B; 88.1 min, 65%35% B; 8.110 min, 35% B. Detection 199 
was performed at 231 nm. The chromatograms were analyzed using the Agilent 200 
ChemStation software (rev. B.01.01), in Windows XP Professional.  201 
 202 
2.3. Reporter gene assays 203 
The detailed descriptions of the reporter gene assays for determination of activities on 204 
several nuclear receptors are given in Supplementary Material S2. 205 
 206 
2.4. 3T3-L1 cell differentiation, RNA isolation and qRT-PCR  207 
The 3T3-L1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 208 
Euroclone), supplemented with 10% fetal bovine serum (Euroclone), 1% L-glutamine 209 
(Euroclone), 100 U/mL penicillin (Sigma), and 100 µg/mL streptomycin (Sigma), at 37 °C. 210 
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Preadipocytes of 3T3-L1 cells were plated at 1.7 ×106 cells in T75 flasks, and grown to 211 
confluence. Two days after reaching confluence (day 0), the cells were stimulated with 212 
differentiation mix (DIM), either alone (DMEM, 10% fetal calf serum, 517 μM 3-isobutyl-213 
1-methylxanthine, 1 μM dexamethasone, 172 nM insulin), or in combination with 214 
increasing concentrations of the bisphenols (final concentrations, 0.1, 1.0, 10 µM). On day 215 
2, the DIM was replaced by insulin medium (DMEM, 10% fetal bovine serum, 172 nM 216 
insulin) alone or with the bisphenols. The medium was subsequently replaced every 2 217 
days until day 8.  218 
To evaluate the activation of the lipidogenic and differentiation marker genes, total 219 
RNA was isolated using the TRIzol reagent (Invitrogen), according to the manufacturer 220 
specifications. One microgram RNA of genomic DNA was purified by DNaseI treatment 221 
(Invitrogen), and random reverse-transcribed with Superscript II (Invitrogen; reaction 222 
volume, 20 μL). Twenty-five nanogram template was added to a PCR mixture (final 223 
volume, 20 μL) containing 0.2 μM each primer and 10 μL 2× SYBR Select Universal ready 224 
mix (Invitrogen). All of the reactions were performed in triplicate, and the thermal cycling 225 
conditions were: 2 min at 95 °C, followed by 40 cycles of 95 °C for 10 s, 60 °C for 45 s 226 
(StepOnePlus instrument; Applied Biosystems). The relative mRNA expression was 227 
calculated and is expressed as 2-(DDCt). The following forward and reverse primer 228 
sequences were used: mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 229 
ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse adiponectin: 230 
gacaggagatcttggaatgaca and gaatgggtacattgggaacagt; mouse Fabp4: 231 
aaacaccgagatttccttcaaa and tcacgcctttcataacacattc; mouse CEBPα: gacatcagcgcctacatcga 232 
and tcggctgtgctggaagag; mouse PPARγ: gccagtttcgatccgtagaa and aatccttggccctctgagat. 233 
 234 
2.5. Nile Red staining 235 
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Differentiated 3T3L1 cells were cultured on 22 × 22 mm glass coverslips, treated, and 236 
then washed three times with phosphate-buffered saline (PBS), and fixed for 15 min with 237 
4% paraformaldehyde. The cells were then rinsed three times with PBS, and stained with 238 
Alexafluor488-conjugated phalloidin (1:100 dilution; ThermoFisher Scientific) and Nile 239 
Red solution (1:500, diluted from 5 mg/mL; ThermoFisher Scientific) in PBS. The cells 240 
were then washed three times with PBS, and mounted on cover slips using SlowFade Gold 241 
mounting medium with DAPI. In-silico fluorescence quantification was carried out 242 
(AxioVision software; Zeiss Microscopy) through the co-localization scatter plots 243 
dedicated tool. The fluorescence-intensity threshold for the red fluorescent signal (i.e., 244 
Nile Red emission) was set to 1000, which is enough to well separate digital noise, cell 245 
autofluorescence background, and low-intensity signals (i.e., membranes) from the high-246 
intensity signals that are typical of lipid droplets and lipid accumulations. Pixels above the 247 
given threshold were then normalized to the control group of cells (set as 100), and 248 
plotted using Graph-Pad Prism 7. 249 
 250 
2.6. Data analysis 251 
The GraphPad Prism 5.04 software for Windows (GraphPad Software Inc., San Diego, CA, 252 
USA) and Microsoft Excel were used to analyze the data obtained in the in-vitro assays for 253 
the different nuclear receptors. The data collected from three independent experiments 254 
were fitted using the GraphPad Prism software, and the representative values were 255 
calculated (i.e., EC50, IC50).  256 
The bisphenols were considered as agonistic for the relevant receptor pathway if 257 
their maximal response level was at least 10% of the maximum response induced by the 258 
positive controls, as 1 nM E2 for estrogenic activity, 0.25 nM T3 for thyroid activity, 0.5 259 
nM dihydrotestosterone for androgenic activity, 500 nM hydrocortisone for 260 
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glucocorticoid activity, 10 μM rifaximin for PXR activity, 10 µM chenodeoxycholic acid 261 
(CDCA) for FXR activity, and 100 nM rosiglitazon for PPARγ activity. Alternatively, the 262 
bisphenols were considered as antagonistic for these receptor pathways if they showed 263 
at least 30% inhibition of the relevant agonist activity. The endocrine-disrupting activities 264 
toward these receptors were analyzed using two-sample student’s t-tests, where *p <0.05, 265 
**p <0.01 and ***p <0.001 were considered statistically significant.  266 
Computation of EC50 values and the statistics was performed using the Graph Pad 267 
Prism 5.04 software. Data are expressed as means ±standard error, while two-group 268 
comparisons used t-test analysis of means with post-hoc Mann–Whitney tests. Differences 269 
were considered statistically significant for p <0.05. 270 
 271 
3. Results 272 
 273 
3.1. BPAF glucuronidation by human liver and intestine microsomes, and by 274 
recombinant human UGTs 275 
The glucuronidation of BPAF was tested using 17 recombinant human UGTs of 276 
subfamilies 1A, 2A, and 2B: UGTs 1A1, 1A3-1A10, 2A1-2A3, 2B4, 2B7, 2B15, 2B17, and 277 
2B28. Two substrate concentrations were used: 20 µM and 50 µM BPAF (Fig. 2A, B). The 278 
highest BPAF glucuronidation rates were seen for the extrahepatic UGTs, particularly 279 
intestinal UGT1A10 and two UGTs that are located mainly in the airways and nasal 280 
epithelium, UGT2A1 and UGT2A2 (which are not expressed in liver or intestine). A 281 
number of the hepatic UGTs catalyzed BPAF glucuronidation: UGT2B7, UGT2B17, 282 
UGT1A9, and UGT1A3, and also UGT1A1, to a lesser degree.  283 
Bisphenol AF glucuronidation rates for HLMs and HIMs were also evaluated to 284 
determine the predominant glucuronidation site of this BPA analog. The BPAF 285 
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glucuronidation rates were about 4-fold higher with HLMs than HIMs (Fig. 2C). The most 286 
likely reason for the higher activity in HLMs is the 20-fold higher expression level of 287 
UGT2B7 in HLMs compared to HIMs, along with the large and meaningful amounts of 288 
UGT1A9 and UGT1A3 in HLMs, which are either not expressed or are barely expressed in 289 
HIMs, at the protein level (Sato et al., 2014). 290 
Bisphenol AF glucuronidation kinetics analyses were performed for the UGTs that 291 
showed significant activities: UGTs 1A3, 1A10, 2A1, 2B7, and 2B17. Most of these BPAF 292 
glucuronidation kinetics followed the substrate inhibition model (i.e., UGTs 1A3, 1A10, 293 
2B7, 2B17), even if they showed different sensitivities for the substrate. The kinetics of 294 
UGT 2A1 were better described by the Michaelis–Menten model (see Data in Brief), and 295 
this extra-hepatic and extra-intestinal UGT showed the highest Vmax (3.30 nmol/min/mg 296 
protein), followed closely by UGT 1A10 (3.03 nmol/min/mg protein). The Vmax for the 297 
largely hepatic UGTs were about one tenth of these (see Data in Brief). On the other hand, 298 
the mainly hepatic UGT 2B7 and UGT 2B17 showed high affinities, with Km of 0.9 µM and 299 
1.12 µM, respectively. 300 
 301 
3.2. BPA, BPAF, and BPAF-G effects on nuclear receptors  302 
Estrogenic activity was determined using a hERα-mediated transactivation assay in 303 
Hela9903 cells, according to the recently available new OECD guideline 455 (Fig. 3). First, 304 
the system responsiveness was confirmed by tests with reference substances. Agonism 305 
toward hERα was tested using E2 as a strong estrogen, 17--estradiol as a weak estrogen, 306 
and corticosterone as a negative control. The data obtained were within the specified 307 
ranges reported previously, with EC50 of 1.91 ×10-5 μM for E2, and 2.24 ×10-3 μM for 17-308 
-estradiol, and with corticosterone showing no activity. BPA and BPAF showed 309 
concentration-dependent agonistic activities toward hERα, while BPAF-G showed no 310 
14 
 
activity toward hERα, as expected. The estrogenic activity of BPAF was 7.5-fold that of 311 
BPA, with EC50 of 0.15 μM and 1.12 μM, respectively (Fig. 3A, Table 2). In contrast to these 312 
agonistic activities, none of these tested bisphenols showed antagonistic activities 313 
towards the hERα pathways (Fig. 3B). The reference substance that was used in the 314 
antagonistic assays was tamoxifen, which showed an IC50 of 0.58 μM (Table 2).  315 
Thyroid endocrine activity was determined with a reporter gene assay in 316 
GH3.TRE-Luc cells, where T3 was used as the positive control, with an EC50 of 0.12 nM. 317 
None of these tested bisphenols showed agonistic thyroid activities (Fig. 3C). In contrast, 318 
BPAF was over 10-fold more potent in its thyroid antagonistic activity than BPA, with IC50 319 
of 7.6 µM and 88.2 µM, respectively (Fig. 3D). BPAF-G showed no activity toward the 320 
thyroid receptors in these GH3.TRE-Luc cells (Fig. 3C, D). 321 
Androgenic and glucocorticoid activities were determined with reporter gene 322 
assays using MDA-kb2 cells, which stably express both androgen and glucocorticoid 323 
receptors. None of the tested bisphenols showed any agonistic activities in this system 324 
(Fig. 3E, G). The controls used in these assays were dihydrotestosterone (androgen 325 
receptor agonist) and hydrocortisone (glucocorticoid receptor agonist), with EC50 of 1.2 326 
×10-3 µM and 0.01 µM for their respective receptor systems. BPAF-G also showed no 327 
antagonistic activities on these MDA-kb2 cells. BPAF and BPA showed antagonistic 328 
androgenic activities in the range of the control flutamide activity, with IC50 of 2.9 µM for 329 
BPAF, 5.5 µM for BPA, and 2.2 µM for flutamide (Fig. 3F). BPA and BPAF also showed 330 
antagonistic glucocorticoid activities, although only at the higher concentrations tested, 331 
and due to their cytotoxicities at >25 µM for BPAF and >50 µM for BPA, their dose-332 
response curves and IC50 could not be determined here (Fig. 3H). 333 
Bisphenol A, BPAF and BPAF-G were also evaluated for their hPXR agonistic (Fig. 334 
4A) and antagonistic (Fig. 4B) activities, using a transactivation assay in HepG2 cells. BPA 335 
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showed the most potent PXR agonistic activity, with an EC50 of 650 nM (Table 2). In 336 
contrast, BPAF and BPAF-G showed PXR antagonistic activities following stimulation with 337 
10 µM rifaximin (PXR agonist). These activities occurred in the low micromolar range for 338 
BPAF and BPAF-G (Table 2).  339 
These bisphenols were also tested for their FXR agonistic (Fig. 4C) and antagonistic 340 
(Fig. 4D) activities in a transactivation assay using FXR-transfected HepG2 cells. The FXR 341 
agonistic activities were initially tested at 10 µM bisphenols, as for CDCA as the positive 342 
control. Significant increases in luciferase expression were only seen with BPAF. The FXR 343 
agonistic activity of BPAF was further confirmed by the dose-response curve, with an EC50 344 
of 5.59 µM (Table 2). Moreover, BPAF was the only bisphenol that showed FXR 345 
antagonistic activity, with an IC50 of 4.9 µM (Table 2). 346 
The PPARγ agonistic and antagonistic activities were then tested for BPA, BPAF 347 
and BPAF-G. Here, none of these showed PPARγ agonistic activities (Fig. 4E), while BPA 348 
and BPAF-G showed dose-dependent antagonistic activities following 100 nM 349 
rosiglitazone (PPARγ agonist), with IC50 of 3.1 µM and 1.7 µM, respectively (Fig. 4F).  350 
 351 
3.3. BPA, BPAF, and BPAF-G effects on lipid accumulation in 3T3L1 preadypocytes 352 
The effects of BPAF and BPAF-G on adipocyte differentiation were also compared with 353 
those of BPA by quantification of lipid accumulation using Nile Red staining. Here, 3T3L1 354 
cells were initially treated with 0.1 M to 10 M BPA for 8 days. This resulted in increased 355 
Nile Red lipid staining in comparison with control cells that were treated with DIM alone, 356 
which indicated a higher differentiation rate with BPA (Fig. 5). Indeed, the quantification 357 
of Nile Red staining indicated significant lipid accumulation even at the lowest tested BPA 358 
concentration (0.1 M), which inducing a >3-fold increase in fluorescence levels relative 359 
to the control. BPAF also significantly increased lipid accumulation at all of the tested 360 
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concentrations (0.1, 1.0, 10 M), although to a significantly lesser extent than its 361 
structural analog BPA at the corresponding concentrations. Interestingly, BPAF-G 362 
increased lipid accumulation at 1 M and 10 M in a dose-dependent manner, 363 
demonstrating a different pattern of effects than seen for both BPA and BPAF, where their 364 
effects at 1 M were higher than at 10 M (Fig. 5). 365 
 366 
3.4. BPA, BPAF, and BPAF-G effects on mRNA expression of transcriptional 367 
regulators of adipogenesis and adipogenic markers in 3T3L1 preadypocytes 368 
To further evaluate the extent of adipocyte differentiation, and to compare the effects 369 
induced by BPA, BPAF, and BPAF-G on differentiation, quantitative real-time PCR was 370 
used to evaluate mRNA expression of four known adipogenic markers: adiponectin, 371 
Fabp4, Cebp, and PPAR. These were determined on days 4 and 8 post-treatment, in 372 
response to 1 M and 10 M bisphenols, relative to the DIM control.  373 
On day 4 post-treatment, both concentrations of BPA showed statistically 374 
significant increases in mRNA levels of the adipogenic marker Fabp4 compared to mRNA 375 
levels for DIM, by 2.3-fold and 4.5-fold, respectively (Fig. 6). Of note, 10 M BPAF-G 376 
increased Fabp4 expression more than BPA, at 5.5-fold relative to DIM. In addition, 10 M 377 
BPA increased the expression of the adipogenic marker adiponectin by 1.6-fold relative 378 
to DIM.  379 
After 8 days of differentiation, the bisphenols maintained the high levels of 380 
adiponectin, especially with 10 M BPA, at a 2.5-fold increase, and 10 M BPAF-G, at a 2.0-381 
fold increase. Instead, 10 M BPAF increased the expression levels of Cebpα, as a 2.0-fold 382 
increase relative to DIM, which is one of the major adipogenic transcription factors for 383 
terminal differentiation. Interestingly, the master regulator of adipogenesis of PPAR 384 
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expression was not increased relative to DIM through the course of differentiation with 385 
these cells treated with BPA, BPAF, and BPAF-G, at both 1 M and 10 M. The other master 386 
regulator of adipogenesis examined here, Cebp, was increased after 8 days with 1 M 387 
and 10 M both BPA and BPAF, relative to the control. For the mature adipocyte marker 388 
Fabp4, the mRNA expression levels were significantly increased mostly after 4 days of 389 
differentiation for these tested bisphenols, and after 8 days of differentiation at 10 M 390 
BPA and BPAF-G.  391 
 392 
4. Discussion 393 
 394 
Recent studies have highlighted the elevated toxicity of BPAF in comparison with other 395 
bisphenols, and have thus raise questions about its safety in terms of human health 396 
(Mokra et al., 2016; Macczak et al., 2017). The present study thus investigated the 397 
influence of glucuronidation of BPAF on some endocrine activities. While the estrogenic 398 
agonistic activities of BPAF and BPAF-G are well known, much less is known about their 399 
activities on other nuclear receptors, and so this was explored in detail here.  400 
Understanding BPAF metabolism is important for the interpretation of its 401 
potential toxicity in humans. It is known that metabolism can enhance endocrine activities 402 
of a compound, as already reported for the BPA oxidative metabolite 4-methyl-2,4-bis(p-403 
hydroxyphenyl)pent-1-ene, which showed about 500-fold higher estrogenic activity than 404 
BPA (Gramec Skledar and Peterlin Masic, 2016). Conjugation reactions are the most 405 
important metabolic transformations for BPAF, and these lead mainly to BPAF-G, and to 406 
a lesser extent, to BPAF sulfate (Gramec Skledar and Peterlin Masic, 2016). The 407 
incubations of BPAF with HLMs and HIMs here showed that its glucuronidation can start 408 
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in the intestine. However, we confirmed that the liver will be the main place for BPAF 409 
glucuronidation, with glucuronidation rates for HLMs about 5-fold those of HIMs.  410 
The next step in the present study was to determine which of a number of UGTs 411 
might be responsible for BPAF glucuronidation. Similar screening of UGTs for BPAF 412 
glucuronidation was performed by Li and coworkers (Li et al., 2013), and they reported 413 
that UGT 2B7 showed the highest BPAF glucuronidation activity. However, here we have 414 
extended their study by including five further UGTs that have never been tested for BPAF 415 
glucuronidation before: UGTs 1A5, 2A1, 2A2, 2A3, and 2B28. The extrahepatic UGTs 2A1 416 
and 2A2, which are mainly expressed in nasal epithelium and airways, and the intestinal 417 
UGT 1A10, showed the highest BPAF glucuronidation rates here. High activities of UGT 418 
2A1 toward different bisphenols was reported previously (Gramec Skledar et al., 2015); 419 
however, for BPAF, this might not be so important, as ingestion with food or liquid would 420 
appear to be the main intake of BPAF. UGT 1A10 is expressed mainly in intestine, and it 421 
showed high BPAF glucuronidation rates, and therefore it might be responsible for 422 
presystemic metabolism of BPAF. This observation is in contrast with the study of Li and 423 
coworkers (Li et al., 2013), where UGT 1A10 showed no activity toward BPAF. However, 424 
it has been confirmed several times that the commercially available UGT 1A10 has low 425 
activity, and therefore that the glucuronidation rates of UGT 1A10 have often been 426 
underestimated (Zhu et al., 2012).  427 
The hepatic UGTs 2B7, 2B17, and 1A3 showed moderate BPAF glucuronidation 428 
rates, while those of UGTs 2B15, 1A9, and 1A1 were low. While these screening data might 429 
appear to be in contrast with the higher BPAF glucuronidation rates in HLMs than HIMs, 430 
there is a logical explanation for this observation: although their BPAF glucuronidation 431 
rates are lower than those of the intestinal UGT 1A10, their expression levels in liver are 432 
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very high. Furthermore, as we determined in the kinetics analysis, the hepatic UGT 2B7 433 
and 2B17 showed very high affinities for BPAF, with Km in the low micromolar range. 434 
In the second part of the present study, we focused on the endocrine activities of 435 
BPAF and BPAF-G, compared to BPA. This is the first study where BPAF and BPAF-G have 436 
been comprehensively studied for their effects on several nuclear receptors in vitro and 437 
in silico, and again, compared to BPA. Both BPA and BPAF showed ER agonistic activity, as 438 
has been reported previously in different in-vitro and in-vivo studies (Table 1), while 439 
BPAF-G was without ER activity. Absence of estrogenic activity has already been 440 
determined for various bisphenol glucuronides; namely, BPA-G (Matthews et al., 2001), 441 
BPS-G (Skledar et al., 2016), and BPAF-G (Li et al., 2013). Our in-silico studies showed that 442 
BPAF-G appears too bulky to fit the binding site of ER, thus providing support for the in-443 
vitro data (see Article in Brief). With the new validated OECD test method 455, BPAF 444 
showed 7.5-fold more potent ER agonistic activity compared to BPA, with EC50 of 0.15 µM 445 
and 1.12 µM, respectively. The estrogenic potencies of BPAF in the low micromolar range 446 
obtained with reporter gene assay on Hela9903 cell line are consistent with estrogenic 447 
assays that have been reported in the literature (Table 1). The potential for ER agonistic 448 
activities of BPA and BPAF was also shown with the molecular modeling, as they showed 449 
similar binding to that of E2. 450 
In addition to the estrogenic activities of bisphenols, which have been the most 451 
studied, they can have significant activities toward several other nuclear receptor 452 
systems, as also confirmed in the present study. Both, BPA and BPAF showed antagonistic 453 
activities toward the androgen and thyroid receptor pathways, although BPAF-G showed 454 
no activity here. The comparable androgenic antagonistic potencies of BPA and BPAF seen 455 
here is in agreement with previous studies (Kitamura et al., 2005; Fic et al., 2014, Kolšek 456 
et al., 2015). Different studies have described antagonist activities of BPA on thyroid 457 
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receptors (Moriyama et al., 2002; Zoeller et al., 2005; Sun et al., 2009); however, there 458 
have only been two in-vitro studies that have described thyroid activity for BPAF, and 459 
their outcomes are contradictory. BPAF showed no thyroid hormone activity when 460 
induction of growth-hormone production was measured in GH3 cells (Kitamura et al., 461 
2005), but showed thyroid hormone receptor agonistic activity using a yeast two-hybrid 462 
assay (Lei et al., 2016). Contrary to these data, we show here potent thyroid antagonistic 463 
activity of BPAF that was about 10-fold that of BPA. With molecular modeling, we showed 464 
that BPA and BPAF, but not BPAF-G, can bind to the T3 binding site. However, in 465 
comparison with T3, they do not offer enough steric and/or binding-interaction 466 
complementarity with the binding site for receptor activation, which supports the 467 
absence of agonist activity on the thyroid receptor in this in-vitro assay. All three of these 468 
bisphenols, BPA, BPAF, and BPAF-G, were without significant glucocorticoid agonistic or 469 
antagonistic activities. This is in agreement with Kolšek et al. (2015), who evaluated BPA 470 
and BPAF glucocorticoid activities using the same cell line as in the present study (i.e., 471 
MDA-kb2 cells). They reported lack activity on glucocorticoid receptors for both BPA and 472 
BPAF at 10 µM (Kolšek et al., 2015). 473 
Many endocrine-disrupting chemicals, including BPA, have been shown to activate 474 
PXR, which is a nuclear receptor that functions as a master regulator of metabolism of 475 
xenobiotics, as well as of endogenous molecules (Sui et al., 2012). PXR is a xenobiotic 476 
sensor that regulates their clearance via induction of genes involved in drug and 477 
xenobiotic metabolism, and it has been implicated in lipid homeostasis, atherosclerosis, 478 
and carcinogenesis (Sui et al., 2014). In the present study, BPA showed potent PXR 479 
agonistic activity (IC50, 0.65 µM). This is in agreement with Sui et al. (Sui et al., 2012), who 480 
reported that BPA is a potent agonist for human PXR, but does not affect mouse PXR 481 
activity. Moreover, the binding mode of BPA in the PXR ligand-binding site is similar to 482 
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that reported by Sui et al. (Sui et al., 2012). In the present study, both BPAF and BPAF-G 483 
were without agonistic activity toward PXR. In contrast, Sui et al. (2012) reported agonist 484 
PXR activity of BPAF at >5 µM. However, induction of luciferase activity in that study was 485 
2 fold greater for BPA than BPAF at all three tested concentrations (i.e., 5 µM, 10 µM, 20 486 
µM), defining BPAF as a weak PXR agonist in comparison with BPA (Sui et al., 2012). 487 
However, in the present study, both BPAF and BPAF-G showed PXR antagonistic activities 488 
in the low micromolar range, thus revealing opposite effects on the modulation of PXR 489 
activity. Antagonistic PXR activity was also confirmed for BPS, using the HepG2/PXR cell 490 
line (Zenata et al., 2017), while BPS was without agonist PXR activity according to two in-491 
vitro studies (Peyre et al., 2014; Zenata et al., 2017). These studies demonstrate that 492 
despite similarities in structure, the same effects on nuclear receptors as observed with 493 
BPA cannot be assumed for its structural analogs. Indeed, while BPA is a PXR agonist, its 494 
analogs BPS and BPAF act as PXR antagonists. 495 
Sui et al. also reported that BPA was inactive on FXR (Sui et al., 2012), and in the 496 
present study, significant agonistic and antagonistic activities toward FXR were only seen 497 
for BPAF, with BPA and BPAF-G without FXR activity. Different binding modes of BPA in 498 
the ligand-binding site of FXR in the agonist-bound and antagonist-bound conformations 499 
were observed by the molecular docking here. In more detail, in the FXR agonist-bound 500 
conformation, BPA can form a hydrogen bond with the Thr288 side chain, which can also 501 
be observed for the agonist MFA-1 (Soisson et al., 2008). Instead, in the FXR antagonist-502 
bound conformation, BPA can interact with the Ala452 and Met456 backbone amides. 503 
It was reported previously that BPA is not a PPARγ agonist, while its halogenated 504 
analogs (brominated, chlorinated BPA analogs), and also their sulfates, act as PPARγ 505 
agonists (Riu et al., 2011a; Riu et al., 2011b). We confirmed here that none of these 506 
bisphenols, BPA, BPAF, and BPAF-G, showed agonistic activities for PPARγ. However, BPA 507 
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and BPAF-G showed PPARγ antagonistic activities, with IC50 in the low micromolar range. 508 
The antagonistic PPARγ activities of those bisphenols have not been tested before. 509 
However, Wright et al (2000) reported that BPA diglycidyl ether can antagonize PPARγ 510 
transcriptional activity induced by the PPARγ agonist rosiglitazone (Wright et al., 2000).  511 
Taken together, BPAF showed strong agonistic activity toward hERα and moderate 512 
(i.e., low micromolar range) antagonistic activities toward the androgen receptor, thyroid 513 
receptor, and PXR. BPAF-G was completely inactive in the reporter assays for hERα, the 514 
androgen, thyroid, and glucocorticoid receptors, and FXR, while it showed antagonistic 515 
activities toward PXR and PPARγ (in the low micromolar range). This thus indicates that 516 
this main metabolite of BPAF, BPAF-G, is not completely inactive, as was proposed in the 517 
past. The most potent activities for all three of these tested bisphenols were the hERα 518 
agonistic activity of BPAF (EC50, 150 nM) and the PXR agonistic activity of BPA (EC50, 650 519 
nM). These justify further studies to evaluate the potential risks for human health. 520 
The present study is the first to report that the BPA analog BPAF, and particularly 521 
BPAF-G, can induce murine 3T3L1 cells to differentiate into adipocytes, as shown here by 522 
the Nile Red lipid staining of these cells after 8 days of differentiation. These and other 523 
data thus suggest that as for BPA, BPA-G (Boucher et al., 2015), and BPS (Ahmed and Atlas, 524 
2016; Boucher et al., 2016), BPAF and its metabolite BPAF-G can increase adipogenesis in 525 
murine preadipocytes. Additionally, we showed increased induction of the adipogenic 526 
genes adiponectin, Fabp4, and Cebpα. In particular, after 4 days of differentiation, BPA 527 
and BPAF-G (even more so), significantly increased expression of Fabp4, the levels of 528 
which are commonly increased at the end of differentiation. Here, the bisphenols induced 529 
high levels of this marker in the early stages of adipocyte differentiation, which were 530 
much higher than in cells treated only with DIM. This indicates their effective impact on 531 
adipogenesis. Conversely, after 8 days of differentiation, BPA and BPAF-G maintained high 532 
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levels of adiponectin, which are usually higher in the early stages of differentiation. 533 
Furthermore, BPA and mostly BPAF increased the expression levels of Cebpα, one of the 534 
major adipogenic transcription factors for terminal differentiation. We can conclude here 535 
that BPA, BPAF, and BPAF-G increase and extend adipocyte differentiation by acting on 536 
target genes that are essential for the different stages of adipogenesis.  537 
Previously, it was shown that BPS can induce lipid accumulation and 538 
differentiation in primary human preadipocytes, and that this effect might be mediated 539 
via direct activation of the nuclear receptor PPARγ. Also, at the human aP2 promoter, 540 
PPARγ activation by BPS is enhanced by activation of the glucocorticoid receptor (Ahmed 541 
and Atlas, 2016; Boucher et al., 2016). Furthermore, these studies also showed that BPA, 542 
BPA-G, and BPS do not directly activate the glucocorticoid receptor to induce 543 
adipogenesis. We show here in the luciferase reporter assays that BPAF and BPAF-G do 544 
not activate the glucocorticoid receptor and PPARγ, which is the master regulator of 545 
adipocyte differentiation. Additional studies will be needed to determine the mechanism 546 
of BPAF-induced and BPAF-G–induced adipogenesis. 547 
 548 
5. Conclusions 549 
 550 
This is the first study where BPAF and BPAF-G have been tested on several nuclear 551 
receptors using reporter cell lines, with comparisons of these activities with their analog 552 
BPA. We can conclude that BPAF is more potent compared to BPA in several luciferase 553 
reporter assays, and so BPAF does not represent a harmless substitute for BPA. 554 
Metabolism of BPAF to BPAF-G eliminates agonistic estrogen and antagonistic androgen 555 
and thyroid activities of BPAF. Nevertheless, BPAF-G shows PXR and PPARγ antagonistic 556 
activities in the low micromolar range. We have shown for the first time that 557 
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glucuronidation of BPAF results in formation of biologically active metabolites. 558 
Additionally, BPAF-G has significant effects on lipid accumulation and differentiation in 559 
murine preadipocytes at 1.0 µM and higher. Thus, in the future, more thorough 560 
toxicological and epidemiological investigations of the BPAF effects on human health are 561 
warranted, to provide a better understanding of the metabolic end-elimination fate of 562 
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Estrogen agonist activity 
YES assay 0.39 3.60 9.2 (Fic et al., 2014) 
Yeast 2-hybrid 5.3 34.1 6.4 (Lei et al., 2016) 
BLYES assay 0.61 4.1 6.7 (Ruan et al., 2015) 
MCF7 luc  0.05 0.63 12.6 (Kitamura et al., 2005) 
CV1 monkey kidney cells 0.097 0.27 2.8 (Teng et al., 2013) 
Androgen antagonist activity 
NIH353  1.3 4.3 3.3 (Kitamura et al., 2005) 
YAS assay 2.29 3.35 1.5 (Fic et al., 2014) 
CV1 monkey kidney cells 1.29 2.34 1.8 (Teng et al., 2013) 
Thyroid agonist activity 
Yeast two-hybrid 1.4 30.1 21.5 (Lei et al., 2016) 
Growth hormone production  NA NA / (Kitamura et al., 2005) 
hPXR agonist activity 
HepG2 cells co-transfected with 
hPXR, CYP3A4-luc reporter, and 
CMX–β-galactosidase plasmid 
* ** / (Sui et al., 2012) 
BLYES, bioluminescence yeast estrogen screen; NA, not active; YAS, yeast androgen 715 
screen; YES, yeast estrogen screen. *BPAF was a relatively weak PXR agonist compared 716 
with BPA; **The half-maximal effective concentration (EC50) for BPA activation of hPXR-717 
mediated cytochrome P450 3A4 (CYP3A4) promoter activity was ~9 μM.  718 
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Table 2: Effects of BPA, BPAF and BPAF-G on estrogen, androgen, thyroid, and 719 









Estrogen Hela9903 Agonistic BPA 1.1 0.87-1.44 
   BPAF 0.15 0.10-0.22 
   BPAF-G NA  
  Antagonistic BPA NA  
   BPAF NA  
   BPAF-G NA  
Androgen MDA-kb2 Agonistic BPA NA  
   BPAF NA  
   BPAF-G NA  
  Antagonistic BPA 5.5 0.63-1.51 
   BPAF 2.9 0.41-1.13 
   BPAF-G NA  
Thyroid GH3.TRE-luc Agonistic BPA NA  
   BPAF NA  
   BPAF-G NA  
  Antagonistic BPA 88 29.2-266.6 
   BPAF 7.6 5.94-9.80 
   BPAF-G NA  
Glucocorticoid MDA-kb2 Agonistic BPA NA  
   BPAF NA  
33 
 
   BPAF-G NA  
  Antagonistic BPA *  
   BPAF *  
   BPAF-G NA  
PXR HepG2 Agonistic BPA 0.65 0.54-0.76 
   BPAF NA  
   BPAF-G NA  
  Antagonistic BPA NA  
   BPAF 3.3 1.45-7.6 
   BPAF-G 3.7 2.04-6.9 
FXR HepG2 Agonistic BPA NA  
   BPAF 5.6 1.38-22.6 
   BPAF-G NA  
  Antagonistic BPA NA  
   BPAF 4.9 2.41-10.22 
   BPAF-G NA  
PPARγ HepG2 Agonistic BPA NA  
   BPAF NA  
   BPAF-G NA  
  Antagonistic BPA 3.1 1.39-6.93 
   BPAF NA  
   BPAF-G 1.7 0.2-15.3 
NA, not active; *Antagonistic activity on the glucocorticoid receptor pathway was 721 
determined at the highest concentrations tested. Due to solubility problems at higher 722 
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Figure legends 726 
 727 
Figure 1. Structures of BPA and BPAF, and the main BPAF metabolite, BPAF-glucuronide. 728 
 729 
Figure 2. BPAF glucuronidation rates for individual UGTs, and human liver (HLM) and 730 
intestinal (HIM) microsomes, in the presence of 20 µM and 50 µM BPAF as substrate. (A) 731 
BPAF glucuronidation rates for the 17 human recombinant UGTs, including some that are 732 
not commercially available. (B) Corrected expression levels for the UGTs in (A) that 733 
showed activities. UGT2B15 was not included, as its expression level could not be 734 
determined (see Materials). (C) BPAF glucuronidation rates in human liver and intestine 735 
microsomes. Data are means ±S.E. of three independent assays. 736 
 737 
Figure 3. Analyses of the agonistic and antagonistic activities of BPA, BPAF, and BPAF-G 738 
toward the estrogen, thyroid hormone, androgen, and glucocorticoid receptors. (A, B) ER 739 
agonistic (A) and antagonistic (B) activities, with the relevant controls (agonist, E2; 740 
antagonist, tamoxifen). (C, D) Thyroid hormone receptor agonistic (C) and antagonistic 741 
(D) activities, with the T3 agonist control. (E, F) Androgen agonistic (E) and antagonistic 742 
(F) activities, with the relevant controls (agonist, dihydrotestosterone; antagonist, 743 
flutamide). (G, H) Glucocorticoid receptor agonistic (G) and antagonistic (H) activities, 744 
with the relevant controls (agonist, hydrocortisone; antagonist, mifepristone). Data are 745 
means ±SE of three independent experiments. See Methods for assay systems used. 746 
 747 
Figure 4. Analyses of the agonistic and antagonistic activities of BPA, BPAF, and BPAF-G 748 
toward PXR, FXR, and PPARγ. (A, B) PXR agonistic (A) and antagonistic (B) activities, with 749 
the relevant agonist control (rifaximim). (C, D) FXR agonistic (C) and antagonistic (D) 750 
36 
 
activities, with the relevant agonist control (CDCA). (E, F) PPARγ agonistic (E) and 751 
antagonistic (F) activities, with the relevant agonist control (rosiglitazon). Data are means 752 
±SE of three independent experiments. See Methods for assay systems used. 753 
 754 
Figure 5. BPA, BPAF, and BPAF-G effects on lipid accumulation in 3T3L1 preadypocytes, 755 
as revealed by Nile Red staining and quantification. 3T3L1 preadipocytes were 756 
differentiated for 8 days in DIM alone, or in combination with BPA, BPAF, or BPAF-G (0.1, 757 
1.0, 10 µM). (A) Representative staining for lipid accumulation on day 8 of differentiation, 758 
with Alexafluor488-conjugated phalloidin and Nile Red (see Methods). (B) Quantification 759 
of fluorescence shown in (A). Data are means ±SE from two experiments, each carried out 760 
in triplicate. *p <0.05 versus cells treated with DIM alone (arbitrarily set to 100).  761 
 762 
Figure 6. BPA, BPAF, and BPAF-G effects on differentiation-related gene expression. 763 
Preadipocyte 3T3L1 cells were differentiated for 4 or 8 days in the presence of DIM alone 764 
(control) or DIM with 1 µM or 10 µM BPA, BPAF, or BPAF-G. Quantification of relative 765 
mRNA expression of adipogenic marker genes: adiponectin, Fabp4, Cebpα, and PPARγ. 766 
Data are means ±SE from two experiments, each carried out in triplicate. *p <0.05 versus 767 
differentiated cells (arbitrarily set to 1). Data are normalized to glyceraldehyde-3-768 
phosphate dehydrogenase mRNA expression, and expressed as 2(-ΔΔCt). 769 
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Figure 4 786 
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Figure 5 793 
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